Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Non-squamous NSCLC × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 HER2 Positive Metastatic Breast Cancer 2 Non-squamous NSCLC 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Breast Cancer 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Breast Cancer 1 Breast Cancer Invasive 1

Interventions

pyrotinib 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04447118 2025-12-19

PYRAMID-1

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed

Non-squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡